Bayer AG Launches China Innovation Hub to Boost Local R&D and Global Integration
Bayer AG (ETR: BAYN), a German multinational pharmaceutical and life sciences giant, has announced the...
Lexicon Pharmaceuticals Strikes Licensing Deal with Viatris for Global Expansion of Sotagliflozin
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) has entered into a licensing agreement with Viatris Inc. (NASDAQ:...
Johnson & Johnson’s Nipocalimab Shows Promise in Treating Adolescent Myasthenia Gravis in Phase II/III Trial
Johnson & Johnson (J&J, NYSE: JNJ), a US pharmaceutical giant, has reported encouraging outcomes from...
NHSA Standardizes NRDL Drug Purchases to Combat Prescription Fraud
The National Healthcare Security Administration (NHSA) has issued a notification aimed at standardizing the management...
Shanxi Province Announces Historic Drug Procurement Batch with 81 Products for 2024
On October 16, 2024, Shanxi Province’s drug procurement platform announced a notice regarding the submission...
Alphamab Oncology and CSPC Pharma’s KN026 Phase III Trial for Breast Cancer Gets NMPA Approval
Alphamab Oncology (HKG: 9966) and CSPC Pharma (HKG: 1093) have jointly announced that their Phase...
Boehringer Ingelheim Pledges USD 5 Million to WHO Foundation for Global Healthcare Advancement
Boehringer Ingelheim (BI), a leading German pharmaceutical company, has joined forces with the World Health...
J&J Reports Q3 2024 Revenue Growth, Raises Full-Year Guidance on Strong Pipeline Progress
Johnson & Johnson (J&J, NYSE: JNJ) has released its financial report for the third quarter...
Shanghai Junshi Biosciences’ Toripalimab Wins Marketing Approvals in India and Hong Kong for Nasopharyngeal Carcinoma
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biotech company based in...
Eli Lilly Launches Medical Innovation Center and Gateway Labs in Beijing to Accelerate Clinical Trials and R&D
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical corporation in the US, has announced...
Jiangsu Hengrui Resubmits Application for Camrelizumab Combo in HCC to FDA
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company based in China, has...
Innovec Biotherapeutics’ IVB103 Gene Therapy for nAMD Receives Clinical Trial Approval from China’s CDE
Beijing InnoVec Biotherapeutics Inc., a leading gene therapy company based in China, has announced that...
Aficamten Market Filing Accepted by China’s CDE for Hypertrophic Cardiomyopathy Treatment
CORXEL, formerly known as Ji Xing Pharmaceuticals and Cytokinetics Inc (CYTK, NASDAQ: CYTK) have achieved...
Jiangsu Hengrui’s Hetrombopag Olamine Receives NMPA Review for Severe Aplastic Anemia Indication
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Hinova Pharmaceuticals Gets NMPA Green Light for HP568 Clinical Study in Breast Cancer
Hinova Pharmaceuticals Inc. (SHA: 688302), a biotech firm based in Chengdu, has announced that it...
Boehringer Ingelheim Partners with Circle Pharma to Develop First-in-Class Cyclin Inhibitor
Boehringer Ingelheim (BI), a leading German pharmaceutical company, has announced a research collaboration and license...
TenNor Therapeutics Secures USD 42.16 Million in Series E Financing for Antibacterial Pipeline
TenNor Therapeutics, a clinical-stage pharmaceutical company based in China, has announced the successful completion of...
Huadong Medicine Gets NMPA Green Light for BCMA-Targeted ADC HDM2027 Phase I/IIa Study
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced that it has...
Lepu Medical Receives Approval for Noninvasive Blood Glucose Meter NeoGlu 01 in China
Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease solutions...
Leqembi, Alzheimer’s Drug by Eisai and Biogen, Now Covered by Qihuibao Insurance in China
Leqembi (lecanemab), an Alzheimer’s disease treatment co-developed by Eisai Co., Ltd (TYO: 4523) and Biogen...